A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE-RESISTANT HBeAg-POSITIVE CHB
单位：[1]Nanfang Hosp, Guangzhou, Guangdong, Peoples R China[2]Ruijin Hosp, Shanghai, Peoples R China[3]You An Hosp, Beijing, Peoples R China[4]Huashan Hosp, Shanghai, Peoples R China[5]Xi Nan Hosp, Chongqing, Peoples R China[6]Peoples Hosp, Beijing, Peoples R China[7]Princess Margaret Hosp, Hong Kong, Hong Kong, Peoples R China[8]Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[9]Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China[10]Fudan Univ, Publ Hlth Ctr, Shanghai 200433, Peoples R China[11]Tuen Mun Hosp, Hong Kong, Hong Kong, Peoples R China[12]Roche, Shanghai, Peoples R China[13]Hoffmann La Roche AG, Basel, Switzerland
第一作者单位：[1]Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Hou J.,Sun J.,Xie Q.,et al.A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE-RESISTANT HBeAg-POSITIVE CHB[J].JOURNAL of HEPATOLOGY.2009,50:S330-S331.doi:10.1016/S0168-8278(09)60912-0.
APA：
Hou, J.,Sun, J.,Xie, Q.,Li, X.,Zhang, J....&Sung, J..(2009).A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE-RESISTANT HBeAg-POSITIVE CHB.JOURNAL of HEPATOLOGY,50,
MLA：
Hou, J.,et al."A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE-RESISTANT HBeAg-POSITIVE CHB".JOURNAL of HEPATOLOGY 50.(2009):S330-S331
医学